Cortechs.ai cleared to automate analysis of amyloid PET brain scans
NeuroQuant PET quantifies amyloid and other tracer uptake to help assess cognitive impairment, including Alzheimer's disease.
Cortechs.ai has received FDA clearance for NeuroQuant PET, software that automatically measures how much of a PET tracer collects in different brain regions. It produces standardized values, including Centiloid scores for amyloid scans, along with structured reports. It is intended to help physicians assess cognitive impairment and conditions such as Alzheimer’s disease.
With newer Alzheimer’s drugs requiring confirmation of amyloid, consistent, automated scan analysis is in growing demand.
Learn more: Cortechs.ai in the Directory